These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10230599)

  • 1. Optic nerve degeneration and potential neuroprotection: implications for glaucoma.
    Schwartz M; Yoles E
    Eur J Ophthalmol; 1999; 9 Suppl 1():S9-11. PubMed ID: 10230599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.
    Yoles E; Wheeler LA; Schwartz M
    Invest Ophthalmol Vis Sci; 1999 Jan; 40(1):65-73. PubMed ID: 9888428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush.
    Yoles E; Muller S; Schwartz M
    J Neurotrauma; 1997 Sep; 14(9):665-75. PubMed ID: 9337128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma.
    Hains BC; Waxman SG
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma.
    Morrison JC; Nylander KB; Lauer AK; Cepurna WO; Johnson E
    Invest Ophthalmol Vis Sci; 1998 Mar; 39(3):526-31. PubMed ID: 9501862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline.
    Levkovitch-Verbin H; Spierer O; Vander S; Dardik R
    Graefes Arch Clin Exp Ophthalmol; 2011 Jun; 249(6):849-57. PubMed ID: 21229256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurodegeneration and neuroprotection].
    Schmidt KG
    Ophthalmologe; 2004 Nov; 101(11):1059-61. PubMed ID: 15449095
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of retinal NMDA receptor activity during autoimmune optic neuritis.
    Bojcevski J; Stojic A; Hoffmann DB; Williams SK; Müller A; Diem R; Fairless R
    J Neurochem; 2020 Jun; 153(6):693-709. PubMed ID: 32031240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of protective effect of local administration of triamcinolone or systemic treatment with methylprednisolone against damages caused by optic nerve crush in rats.
    Huang TL; Chang CH; Lin KH; Sheu MM; Tsai RK
    Exp Eye Res; 2011 Feb; 92(2):112-9. PubMed ID: 21185832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy.
    Brandt C; Potschka H; Löscher W; Ebert U
    Neuroscience; 2003; 118(3):727-40. PubMed ID: 12710980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of 4-(Phenylsulfanyl)butan-2-one on optic nerve crush model in rats.
    Chien JY; Sheu JH; Wen ZH; Tsai RK; Huang SP
    Exp Eye Res; 2016 Feb; 143():148-57. PubMed ID: 26472213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration.
    Neufeld AH
    J Glaucoma; 1998 Dec; 7(6):434-8. PubMed ID: 9871868
    [No Abstract]   [Full Text] [Related]  

  • 13. Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury.
    Zalish M; Lavie V
    Vision Res; 2003 Feb; 43(3):237-42. PubMed ID: 12535983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection: a new treatment modality for glaucoma?
    Schwartz M; Yoles E
    Curr Opin Ophthalmol; 2000 Apr; 11(2):107-11. PubMed ID: 10848215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection--possibilities in perspective.
    Weinreb RN
    Surv Ophthalmol; 2001 May; 45 Suppl 3():S241-2. PubMed ID: 11377442
    [No Abstract]   [Full Text] [Related]  

  • 16. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy.
    Yoles E; Belkin M; Schwartz M
    J Neurotrauma; 1996 Jan; 13(1):49-57. PubMed ID: 8714863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury.
    Wheeler LA; Lai R; Woldemussie E
    Eur J Ophthalmol; 1999; 9 Suppl 1():S17-21. PubMed ID: 10230601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
    Dong CJ; Guo Y; Agey P; Wheeler L; Hare WA
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4515-22. PubMed ID: 18566471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel neuroprotectant against retinal ganglion cell damage in a glaucoma model and an optic nerve crush model in the rat.
    Maeda K; Sawada A; Matsubara M; Nakai Y; Hara A; Yamamoto T
    Invest Ophthalmol Vis Sci; 2004 Mar; 45(3):851-6. PubMed ID: 14985301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation pretreatment does not protect the rat optic nerve from elevated intraocular pressure-induced injury.
    Johnson EC; Cepurna WO; Choi D; Choe TE; Morrison JC
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):412-9. PubMed ID: 25525172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.